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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) has a prevalence of over 20% in Western
societies. Affected individuals are at risk of developing both cirrhosis and hepatocellular cancer (HCC).
Presently there is no cost effective population based means of identifying cirrhotic individuals and even if
there were, our ability to perform HCC surveillance in the at risk group is inadequate. We have performed
a pilot proteomic study to assess this as a strategy for serum biomarker detection.
Methods: 2D Gel electrophoresis was performed on immune depleted sera from 3 groups of patients,
namely those with (1) pre-cirrhotic NAFLD (2) cirrhotic NAFLD and (3) cirrhotic NAFLD with co-existing
HCC. Five spots differentiating at least one of these three groups were characterised by mass
spectroscopy. An ELISA assay was optimised and a cross sectional study assessing one of these serum
spots was performed on serum from 45 patients with steatohepatitis related cirrhosis and HCC and
compared to 77 patients with histologically staged steatohepatitis.
Results: Four of the spots identified were apolipoprotein isoforms, the pattern of which was able to
differentiate the three groups. The 5th spot, seen in the serum of cirrhotic individuals and more markedly
in those with HCC, was identified as CD5 antigen like (CD5L). By ELISA assay, although CD5L was
markedly elevated in a number of cirrhotic individuals with HCC, its overall ability to distinguish non-
cancer from cancer individuals as determined by AUC ROC analysis was poor. However, serum CD5L
was dramatically increased, independently of age, sex, and the presence of necroinflammation, in the serum
of individuals with NAFLD cirrhosis relative to those with pre-cirrhotic disease.
Conclusion: This novel proteomic strategy has identified a number of candidate biomarkers which may
have benefit in the surveillance and diagnosis of individuals with chronic liver disease and/or HCC.
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Globally, viral infections such as Hepatitis B (HBV) and
Hepatitis C (HCV) are the principal causes of chronic liver
injury, while in western nations steatohepatitis secondary
to alcoholic liver disease (ALD) or non-alcoholic fatty
liver disease (NAFLD) contribute significantly. NAFLD is
the liver manifestation of the metabolic syndrome, char-
acterised by central obesity, insulin resistance, hyperten-
sion and atherogenic dyslipidaemia. It is now the
commonest cause of chronic liver disease in western
countries.[1] Whatever the insult, chronic injury generates
a persistent wound healing response associated with a
changing extracellular matrix (ECM) and the accumula-
tion of fibrous, type I collagen rich, scar tissue. Cirrhosis
describes the end stages of this process and is character-
ised by the disruption of normal liver architecture by both
fibrotic bands and disorganised nodules of regenerating
hepatocytes. There is presently no medical treatment to
reverse the changes of cirrhosis, although it is hoped that
improved therapies (eg. antiviral therapy or those target-
ing the metabolic syndrome and/or NAFLD) introduced
at lesser stages of disease may have an impact on their rate
of progression to cirrhosis.
As well as deteriorating liver function and significant clin-
ical morbidity, cirrhosis is associated with a markedly
increased risk of developing hepatocellular carcinoma
(HCC). With more than 500,000 cases diagnosed annu-
ally, HCC itself is a major health problem.[2] It is fre-
quently detected at an advanced, incurable stage [3] and
the survival of those affected has not altered significantly
in the last two decades.[2,4,5] It was hoped that surveil-
lance of cirrhotic individuals would facilitate early diag-
nosis of HCC and improve survival. Surveillance using
liver imaging with abdominal ultrasound (USS) in combi-
nation with serum alpha fetoprotein (AFP) measurement
is performed 6 monthly in many centres. This strategy,
however, has limited value. There is no safe and cost-effec-
tive population-based means to identify the at risk cir-
rhotic population requiring surveillance. Liver biopsy is
presently the best means of diagnosing cirrhosis, but it
carries a significant risk and has well recognised limita-
tions such as sampling error. It is only performed if there
is a clinical indication. There are panels of serum-based
tests,[6] some in conjunction with clinical parameters,
[7,8]now proposed as useful in diagnosing cirrhosis.
These too are largely aimed at individuals in the clinical
setting, rather than being advocated as population-based
screening tools. Despite the prevalence of NAFLD being
2025% of the population,[9] the reality is that many of
those who progress and develop cirrhosis remain unaware
of their disease until a complication, such as an HCC,
develops. Secondly, and even more disheartening for
those with known cirrhosis, the diagnostic performance
of AFP for HCC detection is inadequate [10] as it is only
elevated in 4060% of positive cases. Abdominal USS is lit-
tle better as it is difficult in cirrhotic nodular livers and is
notoriously user dependent.[11] USS in NAFLD patients
is particularly difficult owing to the frequent association
with central obesity.
Improved non-invasive means of detecting both cirrhosis
and HCC are urgently required if we are to have an impact
on the survival of the increasing numbers of individuals
affected by these diseases. Although a number of alterna-
tive biomarkers for HCC have been proposed, largely in
individuals with HCV and some in combination with
AFP, none has yet had an impact on clinical practice. Here
we report our own pilot study in individuals with either
ALD or NAFLD. We have used immune depleted and fil-
tered serum from individuals with liver disease, with and
without cirrhosis, and from cirrhotic individuals with and
without cancer. This serum has been studied using gel-
based proteomic techniques in conjunction with mass
spectroscopy to identify novel biomarkers distinguishing
the three conditions. We have identified 5 candidate
biomarkers capable of discriminating at least one or other
of the patient groups. One novel serum protein, CD5L,
was selected for further characterisation in a larger patient
group. We have confirmed that it is an independent pre-
dictor of cirrhosis in NAFLD, and may also identify indi-
viduals at greater risk of HCC development.
Methods
Patient serum samples
All patient serum and clinical information was collected
with patient consent after approval by The Newcastle and
North Tyneside Ethics Committee. The liver histology of
patients with NAFLD (steatosis on biopsy and compatible
clinical features in the absence of an alcohol intake greater
than 14 units weekly for women and 21 weekly for men)
was staged according to the Brunt scoring system.[12] A
fibrosis score of 4 describes cirrhosis. Serum samples from
patients with chronic liver disease (including both ALD
and NAFLD patients) were taken at the time of liver
biopsy. Individuals with HCC were diagnosed as per
guidelines proposed by the European Association for the
Study of the Liver. [11] The majority of these were not
biopsied, but each of them had an underlying clinical cir-
rhosis in association with a hypervascular lesion visible
on two imaging modalities and compatible with the diag-
nosis of HCC. Serum samples from the individuals with
HCC were pre-treatment samples taken at the time of
diagnosis. Details of the HCC patients and controls with
biopsy proven cirrhosis are included in Table 1. All serum
samples were separated by centrifugation within 4 h and
subsequently stored at -80°C. The standard biochemical
serum tests, including serum AFP, were measured using
routine automated methods in the Biochemistry Labora-
tory at the Freeman Hospital, Newcastle upon Tyne. NoPage 2 of 11
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this study.
Proteomic studies
Serum samples from 5 patients with NAFLD but no signif-
icant fibrosis, 5 patients with NAFLD and biopsy proven
cirrhosis, and 5 patients with NAFLD cirrhosis and
advanced AFP negative HCC were prepared for study. The
samples were immunodepleted by multiple affinity
removal system (MARS HPLC column, 4.6 × 100 mm;
Agilent technologies, UK) and de-salted using 5 K molec-
ular weight cut off spin filters (Agilent technologies, UK).
500 μg of total protein was separated per 2-dimensional
gel electrophoresis run. The prepared protein was first
diluted into a rehydration Buffer comprising 7 M urea, 2
M thiourea, 4% (w/v) CHAPS, 0.5% 310 IPG Buffer (GE
Amersham) and 40 mM DTT and applied to an 18 cm pH
310 NL (GE Amersham) IPG strip. Gel rehydration isoe-
lectric focussing was carried out using an IPGPhor IEF (GE
Amersham) apparatus following the manufacturers stated
running conditions with a final step and hold of 19 kVh.
Subsequently, gel strips were equilibrated in a buffer com-
prising 50 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol,
2% SDS, 0.002% bromophenol blue, containing 100 mg
DTT per 10 ml for 15 min, followed by incubation in the
same solution, but replacing DTT with 250 mg iodoaceta-
mide per 10 ml, for an additional 15 min. Focussed IPG
gel strips were then placed on top of a 25 × 25 cm, 1 mm
thick 12% polyacrylamide gel and overlaid with 0.5% aga-
rose. Resolution in the second dimension was performed
using a DALTsix electrophoresis system (GE Amersham)
running at an initial 5 W per gel for 30 mins, followed by
17 W per gel for approximately 5 hours (max 100 Wh).
Gels were stained using colloidal Coomassie blue (Proto-
Blue Safe Stain, National Diagnostics) following the man-
ufacturers instructions.
All samples were analysed using duplicate gels. Gel
images after scanning were stored as TIFF files and ana-
lysed using Progenesis Software (Nonlinear Dynamics).
Protein spots of interest were excised, destained, and
digested with trypsin. Peptide mass fingerprinting was
performed using a Voyager DE-STR MALDI-TOF mass
spectrometer (Applied Biosystems Inc.) operated in posi-
tive ion reflectron mode with α-cyano-4-hydroxycin-
namic acid as the matrix. Protein identifications were
performed using the Mascot Peptide Mass Fingerprint
search program (Matrix Science Ltd).
Serum ELISA assay
A direct ELISA for novel candidate CD5L was optimised
using different concentrations of serum (raw, 1;10, 1:100,
1:500 and 1:1000), primary anti-CD5L antibody (R&D
systems) and recombinant CD5L protein (R&D systems).
Serum dilutions of either 1:10 or 1:100 generated a linear
absorbance response over a protein range of 0.01  1.0 ng/
ml using a primary antibody dilution of 1:500. This anti-
body dilution was then used to analyse all subsequent
patient serum samples in triplicate at a dilution of 1:10.
Liver Tissues CD5L mRNA analysis
Liver biopsy tissues surplus to diagnostic requirements
were available from 21 patients with histologically staged
pre-cirrhotic NAFLD, collected with appropriate ethical
approvals in either Newcastle Hospitals or the Policlinico
Gemelli Hospital, Rome. Histological staging was as
defined by Brunt [12], although no RNA yield sufficient
for analysis was obtained from a stage 4/cirrhotic biopsy.
In addition, liver tissues obtained at the time of liver resec-
tion or radiofrequency ablation for benign or malignant
primary or secondary tumours was obtained in the New-
castle Hospitals, with ethical approval, from an additional
14 individuals. One of these had histologically confirmed
HCC and steatohepatitis related cirrhosis. The other 13
had 'normal livers', although mild steatosis or a mild focal
mononuclear cell infiltrate were occasionally noted on
histological assessment post resection. Semi-quantitative
real time PCR analysis was performed as previously
described [13] using GAPDH as a control gene and the fol-
lowing CD5L primers: Forward: 5' CAA CAA GCA TGC
CTA TGG CCG AAA, Reverse: 5' TCA CAT TCG ACC CAC
GTG TCT TCA. CD5L expression was expressed relative to
the control gene GAPDH and a normal liver sample from
an individual patient undergoing resection of a benign
focal nodular hyperplasia.
Statistical analysis
Quantitative variables are expressed as mean and standard
deviation. Comparison between groups were performed
Table 1: Clinical characteristics of cirrhotic patients with and 
without HCC.
Cirrhosis HCC
Number 49 45
Age (years) 56.73 ± 8.9 67.8 ± 7.4
Male:Female 35:14 37:8
ALD:NAFLD 28:21 28:17
Childs-Pugh A:B:C 30:14:05 24:16:05
AFP (ng/ml) 6.04 ± 2.68 6551 ± 13602
Bilirubin (μmol/L) 33.42 ± 30.81 22.87 ± 22.29
Albumin (g/l) 36.36 ± 7.76 35.71 ± 5.02
Portal vein invasion NA 8
Single nodule NA 19
Two nodules NA 8
≥ 3 nodules NA 18
The difference in age between patients with cirrhosis and HCC versus 
those with cirrhosis alone was statistically significant (p < 0.001). 
There was no significant difference between sex or Child-Pugh stage 
between the two groups.Page 3 of 11
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appropriate. The diagnostic accuracy of CD5L was evalu-
ated using receiver operating characteristic (ROC) curve
analysis, reporting the area under the curve (AUC) and its
95% confidence interval (CI). Statistical analyses were
performed with SPSS version 14.
Results
Novel candidate biomarkers identified using proteomic 
techniques
Figure 1 shows representative 2D gels of each of the three
groups and identifies a number of spots, labelled 15.
These spots, particularly in combination, enable the dif-
ferentiation between the three patient groups, namely
NAFLD without fibrosis, NAFLD with cirrhosis, and
NAFLD with cirrhosis and HCC.
Protein identification of spots 15 was by Mascot search
after mass spectroscopy. The identities and Mascot scores
are summarised in Table 2. The individual mass spectra
and protein summary information are available as addi-
tional files 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 in the supplemen-
tary information. Spots 13 were all identified after mass
spectroscopy as apolipoprotein A1 (ApoA1). Spot 2 in
particular was reduced in cirrhotic individuals relative to
those with pre-cirrhotic NAFLD. In addition Pro-ApoA1,
spot 3, was markedly present in all individuals with cir-
rhosis and HCC relative to only trace amounts in simple
steatosis patients and cirrhotic patients without HCC. Pro-
tein spot 4 appeared lower in pre-cirrhotic NAFLD
patients, compared to those with cirrhosis and in individ-
uals with cirrhosis and HCC. This spot was identified as
Apolipoprotein A4 (ApoA4). Protein spot 5 was identified
as CD5 antigen like (CD5L). Relative to pre-cirrhotic
NAFLD, this protein was identified in the serum of indi-
viduals with both cirrhosis and also those with cirrhosis
and cancer, markedly so in the latter group.
CD5L determined by ELISA assay was very highly 
expressed in the serum of individuals with cirrhosis and 
HCC
Serum CD5L was assessed in the serum of 45 individuals
with steatohepatitis-related HCC and compared to levels
in 49 individuals with biopsy proven steatohepatitis-
related cirrhosis. Patient characteristics are shown in Table
1. The CD5L serum level was not significantly associated
with age or sex. The box plots depicting the mean levels of
the two groups of patients are shown in Figure 2 and are
not significantly different (194 ± 167 without HCC versus
218 ± 221 with HCC). The AUC determined by ROC anal-
ysis (shown in Figure 2B) was 0.495 and indicated a poor
serum CD5L discriminatory capacity between cirrhotic
Serum proteins separated by two dimensional gel electrophoresis in early and advanced NAFLD, with and without HCCFig re 1
Serum proteins separated by two dimensional gel electrophoresis in early and advanced NAFLD, with and 
without HCC. These are representative blots comparing immune depleted and desalted serum from a patient with NAFLD 
and no fibrosis, a patient with NAFLD cirrhosis, and a patient with NAFLD cirrhosis and cancer. Serum profiles separated by 
2D gel electrophoresis from 5 patients in each group, run in duplicate, were compared using Progenesis software. 5 spots were 
characterised by MS after excision. Spots 1,2 and 3 were isoforms of apolipoprotein A1, spot 4 was apolipoprotein A4, and 
spot 5 was identified as CD5 antigen like, or CD5L.Page 4 of 11
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with HCC did have, however, particularly high CD5L lev-
els. A level greater than 400 ng/ml has a specificity for
HCC of 88%. The sensitivity at this level was unacceptably
poor (20%).
CD5L ELISA in individuals with different stages of NAFLD 
was a good predictor of those with cirrhosis
Serum from 77 patients, all of whom had biopsy proven
NAFLD and had an alcohol intake of < 21 units per week
for men and < 14 units for women, was studied. In this
group of individuals the serum level of CD5L ng/ml in cir-
rhotic individuals (236 ± 223) was similar to those cir-
rhotic individuals with and without HCC described
above. This level for stage 4 fibrosis/cirrhosis was signifi-
cantly elevated compared to individuals with all other
pre-cirrhotic stages (ANOVA p = 0.001, Bonferroni correc-
tion applied). Mean levels of CD5L were not significantly
different between any other histologically defined group
(steatosis or the presence or absence of necroinflamma-
tion). The level of CD5L was significantly associated with
fibrosis independently of age, sex, steatosis or necroin-
flammation, as assessed by General Linear Model analysis
(GLM, SPSS). The ROC analyses of CD5L as a predictor of
stage 4 fibrosis in this independent group of patients with
NAFLD is shown in Figure 3B. The area under the curve
was 0.712 (95% CI 0.5340.889).
CD5L mRNA expression was elevated in individuals with 
NAFLD versus those with no underlying liver disease
CD5L mRNA expression was quantified in one set of liver
biopsy tissues from patients with histologically staged
NAFLD, and a set of normal liver tissues collected at the
time of resection for benign or secondary cancers. (See
methods) Data are expressed relative to the GAPDH con-
trol gene and a single normal liver sample from an indi-
vidual undergoing resection for focal nodular hyperplasia.
In the pre-cirrhotic NAFLD biopsy tissues, there was no
significant difference in association with either fat,
inflammatory or fibrosis score, as shown in Figure 4AC.
What was most notable, was that the liver mRNA expres-
sion of CD5L was significantly increased in the diseased
NAFLD group as a whole (n = 21), relative to the normal
liver group (n = 13) (6.945 ± 0.722 versus1.68 ± 0.269; p
= 0.000). Although some of the 'normal' liver samples
from patients undergoing resection for secondary malig-
nancies had a 'mild steatosis' or a 'minimal focal mono-
nuclear cell infiltrate' noted at the time of histological
examination, there was no significant difference in CD5L
expression in association with either of these minor
changes (data not shown). The marked CD5L mRNA
expression shown in the single cirrhotic tissue and HCC
pair (Figure 4C) were in keeping with the serum ELISA
assays from the much larger patient group.
Discussion
The prevalence of chronic liver disease is increasing stead-
ily in the UK, as is the population at risk of developing
and dying from HCC. An increasing incidence of HCC has
already been documented [5] and this is unfortunately
compounded by the majority of tumours being diagnosed
at a late stage when curative treatments are not possible.
[14] Regular surveillance of high risk individuals is recom-
mended but is presently hindered by the poor perform-
ance of the commonly used serum marker, AFP, [11] even
in combination with abdominal USS. A significant effort
has been and continues to be applied to the search for
improved HCC biomarkers. As yet, none has proved supe-
rior to AFP in performance, but in combination some may
have complimentary roles. [15,16] Our particular concern
relates to the marked increase in the prevalence of ALD
and NAFLD related HCC on our own unit. These individ-
uals are often over 65 years of age and have cardiovascular
co-morbidities precluding curative resection or transplan-
tation. Much attention has been focused on validating
quantitative fibrosis or cirrhosis markers in these individ-
Table 2: The identification of the differentiating protein spots on 2D gels.
Protein Spot Protein Identified by 
Mascot Search
Accession Code 
(Entrez Protein)
Mascot Score (Expect value 
in brackets)*
Sequence Coverage %**
1 ApoA1 (human) CAA00975 247 (6.5e-19) 80
2 ApoA1 (human) CAA00975 236 (8.1e-18) 75
3 Pro-ApoA1 (human)*** CAA00975 195 (1.0e-13) 62
4 ApoA4 (human) AAA51748 338 (5.1e-28) 64
5 CD5L/AIM (human) AAD01446 218 (5.1e-16) 68
The protein spots are as numbered in Figure 1. The * Mascot score is shown as -10*Log(P), where P indicates the probability of a random match. 
Scores > 78 indicate that the protein identification is statistically significant (P < 0.05). ** Sequence coverage from matched peptides in spectra is 
provided in additional figures 110. *** Comparisons between zoomed mass spectra for spots 1 and 2 versus spot 3 are provided in additional figure 
11. The pro-peptide sequence (RHFWQQDEPPQSPWDR...) generates an expected tryptic peptide at m/z = 2109.9 ([M+H]+). Mature ApoA1 
sequence generates a predicted N-terminal tryptic peptide (DEPPQSPWDR...) of m/z = 1226.5 ([M+H]+). AIM = Apoptosis inhibitor expressed by 
Macrophages (alternate name for CD5L).Page 5 of 11
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encouraging if still suboptimal improvements in perform-
ance. Imaging methods such as the fibroscan may
improve the efficiency of cirrhosis detection [17-19], but
presently this technique needs to be interpreted with cau-
tion in obese individuals. [19-23] The need for further
improvements in serum biomarkers for early detection of
both advanced fibrosis and HCC grows ever more press-
ing.
We have applied a proteomic strategy using an optimised
method of patient serum preparation in order to identify
candidate biomarkers of either cirrhosis or HCC. This
includes immune depletion prior to separation of serum
CD5L discriminates poorly between cirrhotic patients with and without HCCFigure 2
CD5L discriminates poorly between cirrhotic 
patients with and without HCC. Serum levels of CD5L 
were measured by ELISA assay in cirrhotic patients with (218 
± 221; n = 45) and without (194 ± 166; n = 49) HCC, as 
shown in 2A. Characteristics of the individuals are shown in 
Table 1. There was no significant difference between the two 
groups. ROC analyses is shown in 2B. The area under the 
curve is 0.495 (95% confidence intervals 0.376 and 0.614). A 
level > 400 ng/ml has a sensitivity of only 20%, but a specifi-
city of 88%. Levels > 500 ng/ml have a specificity of 96%, > 
600 ng/ml of 98% and > 700 ng/ml of 100%. For comparison, 
the mean CD5L serum level from patients without cirrhosis 
(detailed in figure 3) is also shown.
Figure 3Page 6 of 11
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key biomarkers, we believe that this strategy improves the
sensitivity of the technique applied to the remaining
serum proteins. Having identified a number of spots able
to discriminate between patients in at least one of our pre-
defined disease groups, namely pre-cirrhotic NAFLD, cir-
rhotic NAFLD, and cirrhotic NAFLD with cancer, we
selected candidates for identification by peptide mass
spectroscopy.
The novel serum protein CD5L was identified in the
serum of cirrhotic individuals with and without HCC by
our proteomic strategy. CD5L, also known as Sp alpha, is
a soluble protein belonging to group B of the scavenger
receptor cysteine-rich (SRCR) superfamily for which little
functional information is available.[24] It is expressed by
macrophages present in lymphoid tissues (spleen, lymph
node, thymus, and bone marrow), and it binds to myelo-
monocytic and lymphoid cells, suggesting that it may play
an important role in the regulation of the innate and
adaptive immune systems. It was recently identified in the
sera of individuals with liver fibrosis related to HCV infec-
tion and, based on its proposed role in immune system
regulation, was thought most likely associated with viral
infection rather than cirrhosis.[25] While this may yet be
true, as a mRNA transcript, it has been previously reported
upregulated in HCC relative to dysplastic nodules.[26] We
have investigated the potential of CD5L as a candidate
biomarker for either advanced liver disease, or advanced
liver disease and cancer. Our ELISA assay indicated a poor
performance for CD5L as a surveillance tool for HCC, but
again suggested value for cirrhosis detection. Our data
clearly indicate, however, an association with cirrhosis in
individuals without viral infection, which is independent
of the presence or absence of histologically assessed
inflammation. Our CD5L mRNA expression data from
pre-cirrhotic NAFLD liver biopsies indicate an increase in
association with fatty liver disease which, again, is not
altered by the grade of either fat or inflammation. As
CD5L does not increase incrementally with the level or
stage of fibrosis, we propose that its dramatic increase in
the serum of individuals with a background cirrhosis
reflects hepatocyte regeneration, rather than the advanced
fibrosis per se. The recent identification of CD5L by micro-
array as one of 30 mRNA transcripts expressed in patients
with cirrhosis with a 'high risk' of HCC development [27]
was one reason for our focus on this serum protein. Cer-
tainly some of our HCC patients had markedly high CD5L
levels, while those with cirrhosis who had particularly
high levels may be at high risk and may yet develop HCC.
As a cirrhosis biomarker, the ROC analysis for CD5L indi-
cates an accuracy of 72%. While this falls short of the accu-
racy of the European Liver Fibrosis (ELF) panel, recently
validated in NAFLD patients and having an AUC of 0.9 for
advanced fibrosis, CD5L is a single biomarker whose per-
formance in conjunction with others may yet improve. In
addition, it may have a value complementing that of AFP,
which is predominantly elevated in patients with
advanced HCC, in highlighting individuals with cirrhosis
who are at greater risk of HCC development. At a level >
200 ng/ml, CD5L had a specificity for cirrhosis of 96%
and a specificity for cancer of 60%.
Particularly prominent on our gel images were three spots
identified as apolipoprotein A1 (ApoA1). ApoA1 is the
major protein component of high density lipoprotein in
plasma. It promotes cholesterol efflux from tissues to the
liver for excretion and it is a cofactor for lecithin cholester-
olacyltransferase which is responsible for the formation of
most plasma cholesterol esters. It is not that surprising
that this liver function associated protein alters in the
serum of individuals with chronic liver disease and this
has been previously reported in serum proteomic stud-
ies.[28] The mass of spots 1 and 2 (Figure 1) varied by
approximately 30 daltons using MALDI analysis (Addi-
tional files 1 and 3) and are most likely attributable to
post translational modification by oxidation. Notably,
these two spots were reduced in cirrhotic individuals rela-
tive to those with pre-cirrhotic NAFLD, which is in keep-
ing with previous reports and validates the clinical
relevance of our methodology. In fact, a reduction of
ApoA1 in the serum of patients with cirrhosis has
remained a constitutive part of combined peptide panels
used to predict fibrosis for a number of years. [6,29] In
addition, however, we identified a novel isoform  spot 3.
The difference in mass between spots 1 and 2 and spot 3
was much greater and in the order of 900 daltons (Addi-
tional files 1, 3 and 5). MALDI MS analysis of this spot has
identified it as pro-Apolipoprotein A1 (Additional files 6
and 11), similarly detected and reported by an independ-
CD5L discriminates between steatohepatitis patients with and without cirrho isFigure 3
CD5L discriminates between steatohepatitis patients 
with and without cirrhosis. Serum levels of CD5L were 
measured in a total of 113 patients with either ALD or 
NAFLD. Fibrosis was scored histologically on liver biopsy as 
per the Brunt scoring system. The numbers of individuals in 
each group are shown within the boxes of chart 3A. The dif-
ference in CD5L levels between the different stages of fibro-
sis is statistically significant by univariate analysis (p = 0.004) 
controlled for both age and sex. This difference The ROC 
analyses for the identification of those individuals with stage 4 
fibrosis (cirrhosis) is depicted in 3B. The area under the 
curve is 0.719 (95% confidence intervals 0.623 and 0.816), p 
< 0.0001. A level of CD5L 50 ng/ml has a sensitivity of 78% 
and a specificity of 46%, while a level of 100 ng/ml has a sensi-
tivity of 63% and a specificity of 72%. A level greater than 200 
ng/ml has a specificity of 95% (sensitivity 41%), and greater 
than 300 ng/ml of 97% (sensitivity 27%).Page 7 of 11
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cer. [30] Pro-Apolipoprotein A1 is proposed as a novel
serum marker of brain metastases in lung cancer patients
[30] and there may well be a rationale for its upregulation
also in HCC patients. ApoA1 is secreted as the proprotein
(pro-Apolipoprotein A1/spot 3) and is then cleaved, regu-
lating its activation for lipid binding, by a metalloprotei-
nase. One candidate metalloproteinase responsible is the
c-terminal procollagen endoproteinase, Bone morpho-
genic protein 1 (BMP-1). [31] BMP-1 is secreted by the
liver, but protease inhibitors, such as alpha-2-macroglob-
ulin (A2M), are also secreted by the liver, often at elevated
levels in inflammation or chronic disease.[32] Either a
reduction in BMP-1, or an increase in inhibitors such as
A2M  as reportedly occurs in HCC [33], could block the
maturation of pro-Apolipoprotein A1, hence contributing
to relative increase in this isoform (spot 3). In fact, the rel-
ative decrease in mature apoA1 in cirrhotic patients (spot
2) may also reflect increases in protease inhibition and
A2M has similarly contributed significantly to serum diag-
nostic tests for fibrosis. [32,34] Further investigation has
yet to determine the sensitivity and specificity of pro-
Apolipoprotein A1 as a novel candidate biomarker in
patients with chronic liver disease and HCC, but our pilot
study suggests that its up-regulation is specifically a fea-
ture in the serum of patients with HCC.
Conclusion
While non-hypothesis driven methodologies may be crit-
icised by some as 'fishing expeditions', encouraging agree-
ment is beginning to emerge when comparing data
generated by proteomic techniques in the field of chronic
CD5L mRNA expression is not altered in association with either fat, inflammation or fibrosis scores in pre-cirrhotic NAFLD liver tissuesFigure 4
CD5L mRNA expression is not altered in association with either fat, inflammation or fibrosis scores in pre-cir-
rhotic NAFLD liver tissues. mRNA CD5L expression was quantified by real-time PCR, relative to GAPDH and a normal 
liver sample, in 21 pre-cirrhotic NAFLD biopsy tissues, 13 normal liver samples taken at the time of liver resection, one cir-
rhotic liver and one HCC. As shown in 4A-C, there was no difference in any pre-cirrhotic NAFLD biopsy tissues in association 
with the degree of fat, inflammation or fibrosis. There was a significant increase in the NAFLD tissues as a group (n = 21), com-
pared with normal liver tissues (n = 13) as represented in 4D (6.945 ± 0.722 versus1.68 ± 0.269; p = 0.000, ***). The elevated 
CD5L mRNA expression in one cirrhotic and HCC tissue pair, obtained at the time of laparoscopic radiofrequency ablation, is 
also presented in 4C and is in keeping with the elevated serum CD5L levels identified in the larger cohort of patients studied.Page 8 of 11
(page number not for citation purposes)
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text of the ever growing academic literature generated by
gene expression profiling. The data presented in this pilot
study have identified a pattern of serum apolipoproteins
which, in combination with CD5L, can discriminate pre-
cirrhotic NAFLD, cirrhotic NAFLD, and cirrhotic NAFLD
with HCC. These methodologies, even in small pilot stud-
ies requiring additional validation, contribute signifi-
cantly to this field and provide the hope that improved
serum biomarkers may yet become available as surveil-
lance, diagnostic and prognostic tools in patients with
chronic liver disease.
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